129 related articles for article (PubMed ID: 9760678)
1. Endothelin receptor antagonists.
Elliott JD; Ohlstein EH; Peishoff CE; Ellens HM; Lago MA
Pharm Biotechnol; 1998; 11():113-29. PubMed ID: 9760678
[No Abstract] [Full Text] [Related]
2. Enrasetan. SB 217242.
Drugs R D; 1999 Jul; 2(1):24-5. PubMed ID: 10610275
[No Abstract] [Full Text] [Related]
3. 1,3-Diarylindan-2-carboxylic acids, potent and selective non-peptide endothelin receptor antagonists.
Elliott JD; Lago MA; Cousins RD; Gao A; Leber JD; Erhard KF; Nambi P; Elshourbagy NA; Kumar C; Lee JA
J Med Chem; 1994 May; 37(11):1553-7. PubMed ID: 8201588
[No Abstract] [Full Text] [Related]
4. Unmasking of endothelin-1-induced natriuresis and renal vasodilation in the dog by enrasentan (SB 217242).
Brooks DP; DePalma PD
J Cardiovasc Pharmacol; 2000 Nov; 36(5 Suppl 1):S346-7. PubMed ID: 11078416
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and bioactivity of pyrazole acid derivatives as endothelin receptor antagonists.
Cai J; Liu L; Chen J; Cao M; Ji M
Med Chem; 2013 Dec; 9(8):1113-22. PubMed ID: 23521004
[TBL] [Abstract][Full Text] [Related]
6. Endothelin in neurohormonal activation in heart failure.
Boerrigter G; Burnett JC
Coron Artery Dis; 2003 Nov; 14(7):495-500. PubMed ID: 14561942
[No Abstract] [Full Text] [Related]
7. Nonpeptide endothelin receptor antagonists. X. Inhibition of endothelin-1- and hypoxia-induced pulmonary pressor responses in the guinea pig by the endothelin receptor antagonist, SB 217242.
Underwood DC; Bochnowicz S; Osborn RR; Luttmann MA; Hay DW
J Pharmacol Exp Ther; 1997 Dec; 283(3):1130-7. PubMed ID: 9399985
[TBL] [Abstract][Full Text] [Related]
8. Plasma- and cerebrospinal fluid-immunoreactive endothelin-1: effects of nonpeptide endothelin receptor antagonists with diverse affinity profiles for endothelin-A and endothelin-B receptors.
Willette RN; Sauermelch CF; Storer BL; Guiney S; Luengo JI; Xiang JN; Elliott JD; Ohlstein EH
J Cardiovasc Pharmacol; 1998; 31 Suppl 1():S149-57. PubMed ID: 9595425
[TBL] [Abstract][Full Text] [Related]
9. Prediction of the intestinal absorption of endothelin receptor antagonists using three theoretical methods of increasing complexity.
Stenberg P; Luthman K; Ellens H; Lee CP; Smith PL; Lago A; Elliott JD; Artursson P
Pharm Res; 1999 Oct; 16(10):1520-6. PubMed ID: 10554092
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and evaluation of 1,3,6-trisubstituted-4-oxo-1,4-dihydroquinoline-2-carboxylic acid derivatives as ET
Khadtare N; Stephani R; Korlipara V
Bioorg Med Chem Lett; 2017 Jun; 27(11):2281-2285. PubMed ID: 28462837
[TBL] [Abstract][Full Text] [Related]
11. [Discovery of endothelin and its significance].
Goto K
Nihon Rinsho; 2004 Sep; 62 Suppl 9():575-83. PubMed ID: 15506451
[No Abstract] [Full Text] [Related]
12. An efficient approach to the synthesis of 1,3-diaryl-1,2,3,4-[4H]-tetrahydronaphthalene-2-carboxylic acids.
Xiang JN; Nambi P; Ohlstein EH; Elliott JD
Bioorg Med Chem; 1998 Jun; 6(6):695-700. PubMed ID: 9681135
[No Abstract] [Full Text] [Related]
13. New developments in heart failure: role of endothelin and the use of endothelin receptor antagonists.
Suresh DP; Lamba S; Abraham WT
J Card Fail; 2000 Dec; 6(4):359-68. PubMed ID: 11145761
[TBL] [Abstract][Full Text] [Related]
14. Endothelin receptor antagonists: an overview of their synthesis and structure-activity relationship.
Iqbal J; Sanghia R; Das SK
Mini Rev Med Chem; 2005 Apr; 5(4):381-408. PubMed ID: 15853628
[TBL] [Abstract][Full Text] [Related]
15. Effect of SB 217242 on hypoxia-induced cardiopulmonary changes in the high altitude-sensitive rat.
Underwood DC; Bochnowicz S; Osborn RR; Luttmann MA; Louden CS; Hart TK; Elliott JD; Hay DW
Pulm Pharmacol Ther; 1999; 12(1):13-26. PubMed ID: 10208832
[TBL] [Abstract][Full Text] [Related]
16. Solution structure of endothelin B receptor selective antagonist RES-701-1 determined by 1H NMR spectroscopy.
Katahira R; Shibata K; Yamasaki M; Matsuda Y; Yoshida M
Bioorg Med Chem; 1995 Sep; 3(9):1273-80. PubMed ID: 8564420
[TBL] [Abstract][Full Text] [Related]
17. Nonpeptide endothelin receptor antagonists. VI: Pharmacological characterization of SB 217242, a potent and highly bioavailable endothelin receptor antagonist.
Ohlstein EH; Nambi P; Lago A; Hay DW; Beck G; Fong KL; Eddy EP; Smith P; Ellens H; Elliott JD
J Pharmacol Exp Ther; 1996 Feb; 276(2):609-15. PubMed ID: 8632328
[TBL] [Abstract][Full Text] [Related]
18. Effect of novel mixed ETA/ETB antagonists on responses to ET-1 in human small muscular pulmonary arteries.
MacLean MR; Docherty CC; McCulloch KM; Morecroft I
Pulm Pharmacol Ther; 1998; 11(2-3):147-9. PubMed ID: 9918747
[TBL] [Abstract][Full Text] [Related]
19. Glibenclamide reveals role for endothelin in hypoxia-induced vasoconstriction in rat intrapulmonary arteries.
López-Valverde V; Andersen CU; Laursen BE; Mulvany MJ; Simonsen U
J Cardiovasc Pharmacol; 2005 Oct; 46(4):422-9. PubMed ID: 16160592
[TBL] [Abstract][Full Text] [Related]
20. An oral ET(A)-selective endothelin receptor antagonist for contrast nephropathy?
Haylor JL; Morcos SK
Nephrol Dial Transplant; 2001 Jul; 16(7):1336-7. PubMed ID: 11427621
[No Abstract] [Full Text] [Related]
[Next] [New Search]
